Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink
May 2, 2025 9:33 AM EDTLeerink Partners analyst David Risinger reiterated an Outperform rating and $944.00 price target on Eli Lilly (NYSE: LLY), saying yesterday's 12% pullback creates a buying opportunity.
The analyst commented, "Despite LLY downplaying CVS Caremarks action favoring Wegovy over Zepbound, LLY shares declined 11.7% yesterday.... More
